We are live on ! Find out more
GRCL

Gracell Biotechnologies Inc. American Depositary Shares

Delisted

GRCL was delisted on the 21st of February, 2024.

45 hedge funds and large institutions have $134M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

25% more funds holding

Funds holding: 3645 (+9)

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

9% more capital invested

Capital invested by funds: $123M → $134M (+$11.5M)

Holders
45
Holders Change
+9
Holders Change %
+25%
% of All Funds
0%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0%
New
12
Increased
15
Reduced
13
Closed
3
Calls
Puts
Net Calls
Net Calls Change

GRCL Hedge Fund Activity: Q3 2023 in Review

45 institutional investors reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q3 2023, worth a combined $134M — up 9.3% from $123M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new GRCL positions and 3 closed out — a net gain of 9 holders — while 15 added to existing stakes and 13 trimmed.

The largest buyer was Vivo Capital, adding an estimated $25.3M. The largest seller was Great Point Partners, cutting an estimated $6.17M.

  • 45 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q3 2023, up from 36 in Q2 2023.
  • Funds reported $134M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q3 2023, up 9.3% quarter-over-quarter.
  • 12 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q3 2023 and 3 closed out, a net change of +9 holders.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q3 2023 was Vivo Capital, an estimated $25.3M added.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q3 2023 was Great Point Partners, an estimated $6.17M sold.

Based on aggregated 13F filings for Q3 2023.